Home » Newsletters » BioWorld

BioWorld

Feb. 16, 2000

View Archived Issues

NPS Moves Into Phase III Trial With Drug For Osteoporosis

SuperGen, Emisphere, BioPure All Register For Public Offerings

COR Offers $150M Convertible Subordinated Notes Due 2007

Other News To Note

3-Dimensional In $9M Deal With DuPont For Discovery

Genentech, Actelion In $75M Agreement For Heart Drug

Three Biotechs Form Curis To Focus on Tissue Regeneration

Innovation, Funding Expected To Continue Fueling Industry

Pediatric Scientists Try Out FDA-Approved Orphan Drug On Less Rare a-1-Antitrypsin Deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...